IBDEI0LG ; ; 20-MAY-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;OCT 15, 2014
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,10501,0)
 ;;=454.9^^64^684^84
 ;;^UTILITY(U,$J,358.3,10501,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,10501,1,4,0)
 ;;=4^454.9
 ;;^UTILITY(U,$J,358.3,10501,1,5,0)
 ;;=5^Varicose Veins
 ;;^UTILITY(U,$J,358.3,10501,2)
 ;;=^328758
 ;;^UTILITY(U,$J,358.3,10502,0)
 ;;=271.3^^64^685^11
 ;;^UTILITY(U,$J,358.3,10502,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,10502,1,4,0)
 ;;=4^271.3
 ;;^UTILITY(U,$J,358.3,10502,1,5,0)
 ;;=5^Glucose Intolerance
 ;;^UTILITY(U,$J,358.3,10502,2)
 ;;=^64790
 ;;^UTILITY(U,$J,358.3,10503,0)
 ;;=611.1^^64^685^16
 ;;^UTILITY(U,$J,358.3,10503,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,10503,1,4,0)
 ;;=4^611.1
 ;;^UTILITY(U,$J,358.3,10503,1,5,0)
 ;;=5^Gynecomastia
 ;;^UTILITY(U,$J,358.3,10503,2)
 ;;=^60454
 ;;^UTILITY(U,$J,358.3,10504,0)
 ;;=704.1^^64^685^17
 ;;^UTILITY(U,$J,358.3,10504,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,10504,1,4,0)
 ;;=4^704.1
 ;;^UTILITY(U,$J,358.3,10504,1,5,0)
 ;;=5^Hirsutism
 ;;^UTILITY(U,$J,358.3,10504,2)
 ;;=^57407
 ;;^UTILITY(U,$J,358.3,10505,0)
 ;;=251.2^^64^685^30
 ;;^UTILITY(U,$J,358.3,10505,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,10505,1,4,0)
 ;;=4^251.2
 ;;^UTILITY(U,$J,358.3,10505,1,5,0)
 ;;=5^Hypoglycemia NOS
 ;;^UTILITY(U,$J,358.3,10505,2)
 ;;=^60580
 ;;^UTILITY(U,$J,358.3,10506,0)
 ;;=253.2^^64^685^34
 ;;^UTILITY(U,$J,358.3,10506,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,10506,1,4,0)
 ;;=4^253.2
 ;;^UTILITY(U,$J,358.3,10506,1,5,0)
 ;;=5^Hypopituitarism
 ;;^UTILITY(U,$J,358.3,10506,2)
 ;;=^60686
 ;;^UTILITY(U,$J,358.3,10507,0)
 ;;=733.00^^64^685^43
 ;;^UTILITY(U,$J,358.3,10507,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,10507,1,4,0)
 ;;=4^733.00
 ;;^UTILITY(U,$J,358.3,10507,1,5,0)
 ;;=5^Osteoporosis NOS
 ;;^UTILITY(U,$J,358.3,10507,2)
 ;;=^87159
 ;;^UTILITY(U,$J,358.3,10508,0)
 ;;=278.00^^64^685^40
 ;;^UTILITY(U,$J,358.3,10508,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,10508,1,4,0)
 ;;=4^278.00
 ;;^UTILITY(U,$J,358.3,10508,1,5,0)
 ;;=5^Obesity
 ;;^UTILITY(U,$J,358.3,10508,2)
 ;;=^84823
 ;;^UTILITY(U,$J,358.3,10509,0)
 ;;=278.01^^64^685^39
 ;;^UTILITY(U,$J,358.3,10509,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,10509,1,4,0)
 ;;=4^278.01
 ;;^UTILITY(U,$J,358.3,10509,1,5,0)
 ;;=5^Morbid Obesity
 ;;^UTILITY(U,$J,358.3,10509,2)
 ;;=^84844
 ;;^UTILITY(U,$J,358.3,10510,0)
 ;;=250.80^^64^685^10
 ;;^UTILITY(U,$J,358.3,10510,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,10510,1,4,0)
 ;;=4^250.80
 ;;^UTILITY(U,$J,358.3,10510,1,5,0)
 ;;=5^DM Type II with LE Ulcer
 ;;^UTILITY(U,$J,358.3,10510,2)
 ;;=DM Type II with LE Ulcer^267846^707.10
 ;;^UTILITY(U,$J,358.3,10511,0)
 ;;=250.00^^64^685^5
 ;;^UTILITY(U,$J,358.3,10511,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,10511,1,4,0)
 ;;=4^250.00
 ;;^UTILITY(U,$J,358.3,10511,1,5,0)
 ;;=5^DM Type II Dm W/O Complications
 ;;^UTILITY(U,$J,358.3,10511,2)
 ;;=^33605
 ;;^UTILITY(U,$J,358.3,10512,0)
 ;;=250.40^^64^685^6
 ;;^UTILITY(U,$J,358.3,10512,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,10512,1,4,0)
 ;;=4^250.40
 ;;^UTILITY(U,$J,358.3,10512,1,5,0)
 ;;=5^DM Type II Dm with Nephropathy
 ;;^UTILITY(U,$J,358.3,10512,2)
 ;;=^267837^583.81
 ;;^UTILITY(U,$J,358.3,10513,0)
 ;;=250.50^^64^685^9
 ;;^UTILITY(U,$J,358.3,10513,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,10513,1,4,0)
 ;;=4^250.50
 ;;^UTILITY(U,$J,358.3,10513,1,5,0)
 ;;=5^DM Type II w/ PDR
 ;;^UTILITY(U,$J,358.3,10513,2)
 ;;=DM Type II w/ PDR^267839^362.02
 ;;^UTILITY(U,$J,358.3,10514,0)
 ;;=250.60^^64^685^7
 ;;^UTILITY(U,$J,358.3,10514,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,10514,1,4,0)
 ;;=4^250.60
 ;;^UTILITY(U,$J,358.3,10514,1,5,0)
 ;;=5^DM Type II Dm with Neuropathy
